Molecular biology of leukemia for the clinician

Research output: Contribution to journalArticle

Abstract

Although significant progress has been made in the treatment of the acute leukemias, therapies are generally non-specific and not targeted at the biologic defects underlying these diseases. Consequently, treatment results are suboptimal. The development of leukemic cell phenotype-specific therapies is hampered by our limited knowledge of the biology of acute leukemias. That characterizing the genetic defect may revolutionize treatment approach and disease outcome has recently been proven in acute promyelocytic leukemia. Once identified, genes involved in the pathogenesis of leukemic subtypes not only allow for improved diagnosis and monitoring of minimal residual leukemic cells but may ultimately lead to the development of innovative drug strategies that aim at the inhibition of disease-related genes or their encoded proteins. The focus of this review is to familiarize the practicing physician with some principles of molecular biology and with its current and future goals with respect to leukemia.

Original languageEnglish (US)
Pages (from-to)157-166
Number of pages10
JournalMedical Oncology
Volume12
Issue number3
DOIs
StatePublished - Sep 1995

Fingerprint

Molecular Biology
Leukemia
Therapeutics
Acute Promyelocytic Leukemia
Genes
Physicians
Phenotype
Pharmaceutical Preparations
Proteins

Keywords

  • Leukemia
  • molecular biology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Molecular biology of leukemia for the clinician. / Paietta, Elisabeth M.

In: Medical Oncology, Vol. 12, No. 3, 09.1995, p. 157-166.

Research output: Contribution to journalArticle

@article{28f6620f6dff4e088312ecf1079c0bed,
title = "Molecular biology of leukemia for the clinician",
abstract = "Although significant progress has been made in the treatment of the acute leukemias, therapies are generally non-specific and not targeted at the biologic defects underlying these diseases. Consequently, treatment results are suboptimal. The development of leukemic cell phenotype-specific therapies is hampered by our limited knowledge of the biology of acute leukemias. That characterizing the genetic defect may revolutionize treatment approach and disease outcome has recently been proven in acute promyelocytic leukemia. Once identified, genes involved in the pathogenesis of leukemic subtypes not only allow for improved diagnosis and monitoring of minimal residual leukemic cells but may ultimately lead to the development of innovative drug strategies that aim at the inhibition of disease-related genes or their encoded proteins. The focus of this review is to familiarize the practicing physician with some principles of molecular biology and with its current and future goals with respect to leukemia.",
keywords = "Leukemia, molecular biology",
author = "Paietta, {Elisabeth M.}",
year = "1995",
month = "9",
doi = "10.1007/BF01571193",
language = "English (US)",
volume = "12",
pages = "157--166",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Molecular biology of leukemia for the clinician

AU - Paietta, Elisabeth M.

PY - 1995/9

Y1 - 1995/9

N2 - Although significant progress has been made in the treatment of the acute leukemias, therapies are generally non-specific and not targeted at the biologic defects underlying these diseases. Consequently, treatment results are suboptimal. The development of leukemic cell phenotype-specific therapies is hampered by our limited knowledge of the biology of acute leukemias. That characterizing the genetic defect may revolutionize treatment approach and disease outcome has recently been proven in acute promyelocytic leukemia. Once identified, genes involved in the pathogenesis of leukemic subtypes not only allow for improved diagnosis and monitoring of minimal residual leukemic cells but may ultimately lead to the development of innovative drug strategies that aim at the inhibition of disease-related genes or their encoded proteins. The focus of this review is to familiarize the practicing physician with some principles of molecular biology and with its current and future goals with respect to leukemia.

AB - Although significant progress has been made in the treatment of the acute leukemias, therapies are generally non-specific and not targeted at the biologic defects underlying these diseases. Consequently, treatment results are suboptimal. The development of leukemic cell phenotype-specific therapies is hampered by our limited knowledge of the biology of acute leukemias. That characterizing the genetic defect may revolutionize treatment approach and disease outcome has recently been proven in acute promyelocytic leukemia. Once identified, genes involved in the pathogenesis of leukemic subtypes not only allow for improved diagnosis and monitoring of minimal residual leukemic cells but may ultimately lead to the development of innovative drug strategies that aim at the inhibition of disease-related genes or their encoded proteins. The focus of this review is to familiarize the practicing physician with some principles of molecular biology and with its current and future goals with respect to leukemia.

KW - Leukemia

KW - molecular biology

UR - http://www.scopus.com/inward/record.url?scp=0029552965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029552965&partnerID=8YFLogxK

U2 - 10.1007/BF01571193

DO - 10.1007/BF01571193

M3 - Article

C2 - 8852398

AN - SCOPUS:0029552965

VL - 12

SP - 157

EP - 166

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 3

ER -